Edward Dolk, Sales:
Edward Dolk is active for over 14 years in applied science using llama antibody technology. He started at Unilever NV working on protein secretion by yeast, which was followed by a PhD track on the stability of VHH in application conditions. After this Edward Dolk has been developing VHH for therapeutics in collaboration with Ablynx NV at Utrecht University. This work resulted in two first author papers on llama antibody fragments and co-inventorship on 10 patents on llama antibody fragments (nanobodies). He is a strong communicator and networker and has built up an impressive network in the scientific and business communities.